Sirna Therapeutics to Present at Bank of America 2006 Specialty Pharmaceuticals Conference
03 August 2006 - 11:07PM
PR Newswire (US)
SAN FRANCISCO, Aug. 3 /PRNewswire-FirstCall/ -- Sirna Therapeutics,
Inc. ("Sirna") (NASDAQ:RNAI), a leading RNAi therapeutics company,
announced today that Bharat M. Chowrira, Ph.D., J.D., VP-Legal
Affairs and Chief Patent Counsel, is scheduled to give a company
presentation at the Bank of America 2006 Specialty Pharmaceuticals
Conference on Friday, August 11, 2006 at 11:15 a.m. EDT at the
Southampton Inn in Southampton, NY. For more information on this
conference, please log onto http://www.bofa.com/corporateevents .
About Sirna Therapeutics Sirna Therapeutics is a clinical-stage
biotechnology company developing RNAi-based therapies for serious
diseases and conditions, including age-related macular degeneration
(AMD), hepatitis B and C, dermatology, asthma, RSV, Huntington's
disease, diabetes and oncology. Sirna Therapeutics completed its
Phase 1 clinical trial for Sirna-027 in AMD in 2005 and with its
strategic partner, Allergan, Inc., will move Sirna-027 into Phase 2
clinical trials in 2006. Sirna has selected a clinical compound for
hepatitis C virus, Sirna-034, which the Company plans to bring into
Phase 1 clinical trials by the end of 2006. Sirna has established
an exclusive multi-year strategic alliance with GlaxoSmithKline for
the development of siRNA compounds for the treatment of respiratory
diseases. Sirna has a leading intellectual property portfolio in
RNAi covering over 250 mammalian gene and viral targets and over
200 issued or pending patents covering other major aspects of RNAi
technology, including the microRNA technology. More information on
Sirna Therapeutics is available on the Company's web site at
http://www.sirna.com/. Safe Harbor Statement Statements in this
press release which are not strictly historical are
"forward-looking" statements which should be considered as subject
to many risks and uncertainties. For example, most drug candidates
do not become approved drugs. Sirna currently does not have any
clinical drug candidates for the treatment of respiratory diseases,
and the development of Sirna-027 and Sirna-034 as well as Sirna's
other programs are still at a relatively early stage. All of these
programs, and Sirna's ability to obtain milestone and royalty
payments for them, are subject to significant risks and unknowns,
are highly contingent upon future successes, and require
significant funding. In addition, patent applications may not
result in issued patents, and issued patents may not be enforceable
or could be invalidated. Other risks and uncertainties include,
among others, Sirna's early stage of development and short
operating history, Sirna's history and expectation of losses and
need to raise capital, Sirna's need to obtain clinical validation
and regulatory approval for Sirna-027, Sirna-034 and Sirna's other
product candidates, any of which could have negative results,
Sirna's need to engage collaborators, Sirna's need to obtain and
protect intellectual property, and the risk of third-party patent
infringement claims. These and additional risk factors are
identified in Sirna's Securities and Exchange Commission filings,
including Forms 10-K and 10-Q and in other SEC filings. Sirna
undertakes no obligation to revise or update any forward-looking
statements in order to reflect events or circumstances that may
arise after the date of this release. Contacts: Stephan Herrera
Executive Director of Investor Relations Sirna Therapeutics, Inc.
415-512-7200; Brandon Belcher The Ruth Group (646) 536-7009;
DATASOURCE: Sirna Therapeutics, Inc. CONTACT: Stephan Herrera,
Executive Director of Investor Relations of Sirna Therapeutics,
Inc., +1-415-512-7200, ; or Brandon Belcher of The Ruth Group,
+1-646-536-7009, , for Sirna Therapeutics, Inc. Web site:
http://www.sirna.com/ http://www.bofa.com/corporateevents
Copyright
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sirna Therapeutics (NASDAQ:RNAI)
Historical Stock Chart
From Sep 2023 to Sep 2024